Clene announces evidence from post-hoc analysis of HEALY ALS platform trial
Clene (CLNN) and its subsidiary, Clene Nanomedicine announced new evidence from a cross-regimen, post hoc analysis of long-term survival in ...
Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment
New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival AdvantageSALT LAKE CITY, March 12, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene ...
Nature1mon
Nature Research Intelligence Topics
Nature Research Intelligence Topics enable transformational understanding and discovery in research by categorising any document into meaningful, accessible topics. Read this blog to understand ...